Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens (BionAtlanta)

This study has been completed.
Sponsor:
Collaborator:
Chr Hansen A/S
Information provided by (Responsible Party):
Merck Medication Familiale
ClinicalTrials.gov Identifier:
NCT01096615
First received: March 30, 2010
Last updated: July 25, 2012
Last verified: July 2012
  Purpose

The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (probiotic Lactobacillus paracasei LP-33)(as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.


Condition Intervention Phase
Rhinitis
Dietary Supplement: Placebo
Dietary Supplement: Lactobacillus paracasei LP-33
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project

Resource links provided by NLM:


Further study details as provided by Merck Medication Familiale:

Primary Outcome Measures:
  • The primary criterion is the RQLQ global score measured at the end of Week 0 and Week 5. [ Time Frame: Week 0 and Week 5 ] [ Designated as safety issue: No ]

    The RQLQ includes 28 questions (completed between 10-15 min). Subjects are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale (0 = no impairment, 6 = severe impairment). The RQLQ score ranges from 0 to 6. This questionnaire will be filled in by volunteers on D0 and D35.

    The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.



Secondary Outcome Measures:
  • To show a decrease in allergic rhinitis symptoms on the 5th week of product consumption (as assessed by RQLQ and RTSS-5) [ Time Frame: Week 0-Week 5 ] [ Designated as safety issue: No ]
  • To show an increase in the time of 1st exacerbation of symptoms of rhinitis symptom with Lactobacillus paracasei LP-33 [ Time Frame: Week 5- Week 7 ] [ Designated as safety issue: No ]

Enrollment: 500
Study Start Date: April 2010
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Tested product: Lactobacillus paracasei LP-33
Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
Dietary Supplement: Lactobacillus paracasei LP-33

Description:

  • minimum 2.0x109 CFU of Lactobacillus paracasei LP-33
  • capsule size 3 1 capsule daily together with a meal, with a glass of water.
Placebo Comparator: Comparative product : placebo
Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
Dietary Supplement: Placebo

Description:

- capsule size 3

Composition of the product:

  • 45 mg of microcristalline cellulose,
  • 132 mg of maltodextrin,
  • 3 mg of magnesium stearate.

Composition of the capsule:

  • 46 mg of hypromellose,
  • 1 mg of titanium dioxide.

Packaging:

Products are packaged in aluminium tubes of 30 capsules.

Storage:

The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.

The study products will be consumed daily for 7 weeks.


Detailed Description:

Oral H1-antihistamines are first treatment recommended for allergic rhinitis (Bousquet et al, 2008) however they do not completely alleviate symptoms. This new study will therefore assess the effect of Lactobacillus paracasei LP-33 in the management of nasal and ocular symptoms, in addition to H1-antihistamines treatment. The main objective is to evaluate the effect of Lactobacillus paracasei LP-33 on quality of life. Additionally allergic rhinitis symptoms (nasal and eye symptoms) and immunological parameters will be evaluated, before and during the supplementation. Lactobacillus paracasei LP-33 is targeting the general population and improving quality of life of people sensitized to allergens. The study will be conducted in Europe on adult subjects with persistent allergic rhinitis.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects;
  • Aged 18 to 60 years;
  • People with nasal and ocular discomfort at least sensitized to grass pollen;
  • Subject with PER allergy (persistent form) as defined by ARIA guidelines or with a recurrent history of seasonal allergic rhinitis documented by treatment intakes in his medical dossier.
  • Previous positive skin prick test or presence of specific serum IgE antibodies class II or above against timothy grass in the last 5 years. If no data are available, a test for detection of timothy grass specific serum IgE antibodies (Phadia CAP System) will be performed at the pre-inclusion visit;
  • With RQLQ score ≥ 2;
  • Subjects agree to stop consumption of probiotics (food or dietary supplement containing probiotics) and vitamins and/or minerals during the study (D-10/D-7 to D49).

Female subjects with efficient contraception and asthmatic subjects (with a controlled disease and without oral corticosteroid) can be included in the study.

The baseline period prior to treatment with Lactobacillus paracasei LP-33 is 7 days. On recommendations of the consulted experts, Pr Bousquet and Pr Hamelmann, a wash-out period of 3 additional days is recommended before baseline for subject using intranasal corticosteroid before their inclusion. As a consequence, the baseline may be extended to 10 days for these subjects In case the subject consumed an anti-H1 (other than Loratadine) before his (her) inclusion, he (she) will have to switch to Loratadine to be included.

Exclusion Criteria:

  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;

    • Presenting a psychological incapability or having a bad comprehension of the language (French or German according to the concerned country) to understand the information letter and then to sign the informed consent;
    • Refusing to sign the informed consent;
    • Adult under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
    • Pregnant or breastfeeding women;
    • Use of medication which could interfere with the study in the investigator's opinion (antibiotics, etc…);
    • Subject who does not agree to stop his/her consumption of dietary supplements and foods containing probiotics and his/her supplementation of vitamins/minerals during the study (D-10/D-7 to D49).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01096615

  Hide Study Locations
Locations
France
Corinne SION
Aix En Provence, France, 13100
Philippe PIAT
Ales, France, 30100
Alain FAUDIN
Ales, France, 30100
Sylvie CHABROL-RIVIERE
Ales, France, 30100
Daniel FERET
Aubevoye, France, 27940
Florian KOMAC
Aubord, France, 30620
Alain GIACOMINO
Avoine, France, 37420
Jean DEFLAUX
Beaucaire, France, 30300
Sébastien CONVENT
Beauvoisin, France, 30640
Gabriel VENTURINI
Beziers, France, 34500
Robert COMBET
Beziers, France, 34500
Thierry STEFANAGGI
Beziers, France, 34500
Emmanuel DEJOUX
Beziers, France, 34500
Nicolas BRETON
Beziers, France, 34500
Catherine BRUNET-CAZOT
Beziers, France, 34500
Sophie ROSENBERG
Bischeim, France, 67800
Sabine GRUTTER
Bischeim, France, 67800
Olivier BISCH
Bischeim, France, 67800
Jacques RAMBAUD
Bompas, France, 66430
Chantal MARTIN
Bouillargues, France, 30230
Catherine AYRAL
Boujan Sur Libron, France, 34760
Laurence DAGES
Bourg Achard, France, 27310
Dominique EDET
Bretteville L'orgueilleuse, France, 14740
Didier CADINOT
Broglie, France, 27270
François LE HINGRAT
Calvisson, France, 30420
Bernadette CHAUFFAILLE
Castelnau Le Lez, France, 34170
Georges BINET
Castelnaudary, France, 11400
Hervé VILAREM
Castelnaudary, France, 11400
Marc GARCIA
Clarensac, France, 30870
Gladys HAVARD
Clarensac, France, 30870
Michel AMOUYAL
Codognan, France, 30920
Nicole FERRIER
Codognan, France, 30920
Philippe GRUJARD
Colombelles, France, 14460
Philippe HEUZE
Cournonsec, France, 34660
Gregoire MARTOCQ
Cournonterrac, France, 34660
Bruno DAUBIN
Coursan, France, 11110
Jean-Baptiste DE LEMOS
Damville, France, 27240
Marcel RUETSCH
Dessenheim, France, 68600
Christian DAUGENET
Equeurdreville Hainneville, France, 50120
Gérard DUGNY
Evreux, France, 27000
Thierry CANALI
Evreux, France, 27000
Frédéric RENOU
Fecamp, France, 76400
Pascal MABIRE
Fleury Sur Orne, France, 14123
Alain LION
Gambsheim, France, 67760
Raymond WESTERFELD
Hangenbieten, France, 67980
Gérard TELLIER
Hautot Sur Mer, France, 76550
Marc BUR
Herlisheim, France, 67850
Jean Pascal SASTOURNE
Ille Sur Tet, France, 66130
Reinhard RENNER
Laroque Des Alberes, France, 66740
Christian FLAISSIER
Lasalle, France, 30460
Irène LAFONT
Lasalle, France, 30460
Patrick DUTILLEUL
Le Cailar, France, 30740
Claude BRUNAUD
Lignan Sur Orb, France, 34490
Jean-Philippe RICHTER
Lingolsheim, France, 67380
Stéphane BOURGHOL
Marguerittes, France, 30320
Maurice GAY
Maurin, France, 34970
Patrick OLOMBEL
Meze, France, 34140
Victor BASTIDE
Montpellier, France, 34000
Marie Pascale DEMOLY
Montpellier, France, 34000
Philippe CAYRON
Montpellier, France, 34070
Jean Pierre CANO
Montpellier, France, 34080
Jean François GUILLEM
Montpellier, France, 34000
MONGIN
Montpellier, France, 34000
Jean Roch ALEA
Montpellier, France, 34000
Cécile BELIN-SAUGET
Montpellier, France, 30090
Thierry AUTARD
Montpellier, France, 34000
Michel CHASSAGNE
Montpellier, France, 34070
Patrick VOGT
Mulhouse, France, 68200
Jean-Louis WURTZ
Mundolsheim, France, 67450
Marie Christine BONS-GALLET
Nimes, France, 30900
Paul REGNIER-VIGOUROUX
Nimes, France, 30000
Dominique BLOT
Nimes, France, 30900
Nasser GOUCHENE
Nimes, France, 30000
Philippe IMBERT
Nimes, France, 30900
Claude BERNAT
Nimes, France, 30900
COSTA
Nîmes, France, 30920
Yves-Olivier SCHLECHT
Obernai, France, 67210
Natacha HEITZ
Obernai, France, 67210
Georgios MARKIDIS
Obernai, France, 67210
Guy BIRRY
Ottrott, France, 67530
Bernard PRIJAC
Pacy Sur Eure, France, 27120
Alain GUERRI
Perpignan, France, 66000
Gérard BOURREL
Perpignan, France, 66000
Chantal MALZAC
Perpignan, France, 66000
Serge ELIE
Pompignan, France, 30170
Sonia COURTOIS
Pont de L'arche, France, 27340
Bernard GABBAI
Pont Saint Esprit, France, 30130
Geneviève DURANT
Rivesaltes, France, 66600
Olivier BAISSAS
Rouen, France, 76000
Baudoin PINSON
Rouen, France, 76000
Sylvie OLLIVIER
Rousson, France, 30340
Dominique GENOUD
Rousson, France, 30340
Patrick VERDAVOINE
Rugles, France, 27250
Catherine MERCEY
Saint Genis Des Fontaines, France, 66740
Yves MERCEY
Saint Genis Des Fontaines, France, 66740
Béatrice LOGNOS-FOLCO
Saint Georges D'orques, France, 34680
Jean-Yves DOERR
Saint Sebastien de Morsent, France, 27180
Martine FERRE
Saint Siffret, France, 30700
Gil MEYRAND
Sainte Anastasie, France, 30190
Jean Baptiste THIBERT
Salses Le Chateau, France, 66600
Raymond ATTUIL
Schilttigheim, France, 67300
Monique LESCOUTE
Schilttigheim, France, 67300
Léa ABOAF
Schilttigheim, France, 67300
Luc ECHINARD
Sete, France, 34200
Laurent TENNEZE
Sommieres, France, 30250
Charles LOUSQUI
Strasbourg, France, 67000
Claire ROLLAND-JACQUEMIN
Strasbourg, France, 67000
Joël ETIENNEZ
Strasbourg, France, 67000
Maxime BOUMANDIL
Strasbourg, France, 67100
Judah TOLEDANO
Strasbourg, France, 67000
Hélène STURCHLER
Strasbourg, France, 67000
Philippe MARMOR
Strasbourg, France, 67000
Patrick KORMANN
Strasbourg, France, 67000
Véronique PEREZ
Strasbourg, France, 67000
Claire PFRUNNER-SCHNEIDER
Strasbourg, France, 67000
Roland BENEDIC
Strasbourg, France, 67000
Nathan ABENHAIM
Strasbourg, France, 67000
Hervé MOREL
Tilly Sur Seulles, France, 14250
Jacques GRAVES
Trebes, France, 11800
Bernard CLARY
Trebes, France, 11800
Eric LIOTARD
Uchaud, France, 30620
Christian GIRARD
Uchaud, France, 30620
Olivier CHAIX
Uzes, France, 30700
François BAYLE
Valleraugue, France, 30570
Philippe BOISSON
Ville, France, 67220
Sponsors and Collaborators
Merck Medication Familiale
Chr Hansen A/S
Investigators
Study Chair: Jean BOUSQUET, Pr
  More Information

No publications provided

Responsible Party: Merck Medication Familiale
ClinicalTrials.gov Identifier: NCT01096615     History of Changes
Other Study ID Numbers: 13609
Study First Received: March 30, 2010
Last Updated: July 25, 2012
Health Authority: France: Institutional Ethical Committee

Keywords provided by Merck Medication Familiale:
Allergic rhinitis-Probiotic Lactobacillus paracasei LP-33-

Additional relevant MeSH terms:
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on June 17, 2013